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Cellular/Molecular
Egr-1 Induces DARPP-32 Expression in Striatal Medium
Spiny Neurons via a Conserved Intragenic Element
Serene Keilani,1 Samira Chandwani,1 Georgia Dolios,2 Alexey Bogush,3Heike Beck,4 Antonis K. Hatzopoulos,5
Gadiparthi N. Rao,6 Elizabeth A. Thomas,7 RongWang,2 andMichelle E. Ehrlich1,2
Departments of 1Neurology and Pediatrics and 2Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, 3Weinberg
Unit for ALS Research, Department of Neuroscience, Farber Institute for Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania 19107,
4Walter Brendel Center of Experimental Medicine, Ludwig Maximilians University, D-81377 Munich, Germany, 5Division of Cardiovascular Medicine,
Department of Medicine, Vanderbilt University, Nashville, Tennessee 37240, 6Department of Physiology, University of Tennessee Health Science Center,
Memphis, Tennessee 38163, and 7Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037
DARPP-32 (dopamine and adenosine 3, 5-cyclic monophosphate cAMP-regulated phosphoprotein, 32 kDa) is a striatal-enriched
protein thatmediates signaling by dopamine and other first messengers in themedium spiny neurons. The transcriptional mechanisms
that regulate striatal DARPP-32 expression remain enigmatic and are a subject of much interest in the efforts to induce a striatal
phenotype in stem cells. We report the identification and characterization of a conserved region, also known as H10, in intron IV of the
gene that codes for DARPP-32 (Ppp1r1b). This DNA sequence forms multiunit complexes with nuclear proteins from adult and embry-
onic striata of mice and rats. Purification of proteins from these complexes identified early growth response-1 (Egr-1). The interaction
between Egr-1 and H10 was confirmed in vitro and in vivo by super-shift and chromatin immunoprecipitation assays, respectively.
Importantly, brain-derivedneurotrophic factor (BDNF), a known inducer ofDARPP-32 andEgr-1 expression, enhancedEgr-1 binding to
H10 in vitro. Moreover, overexpression of Egr-1 in primary striatal neurons induced the expression of DARPP-32, whereas a dominant-
negative Egr-1 blocked DARPP-32 induction by BDNF. Together, this study identifies Egr-1 as a transcriptional activator of the Ppp1r1b
gene and provides insight into the molecular mechanisms that regulate medium spiny neuron maturation.
Introduction
Gene expression in striatal medium spiny neurons (MSNs) is
altered in a number of neuropsychiatric diseases, e.g., Hunting-
ton’s disease (HD). There is dysregulation in the expression of
ubiquitous and striatal-enriched transcription factors (TFs) in
the caudate nucleus in multiple HD mouse models and human
HD subjects, which may contribute to the downregulation in the
expression of striatal-enriched proteins (Luthi-Carter et al., 2000,
2002; Zucker et al., 2005; Hodges et al., 2006; Thomas et al.,
2011). However, these TFs and their targets, i.e., markers of ter-
minally differentiated MSNs, have not been linked.
MSNs are GABAergic and contribute to regulation of move-
ment, organization of motor behavior, and cognition (Gerfen,
1992; Jain et al., 2001; Graybiel, 2005). They project to the globus
pallidus or substantia nigra (Gerfen and Young, 1988), and they
receive glutamatergic synaptic inputs from the cerebral cortex
and dopaminergic afferents from the substantia nigra and ventral
tegmental area (Parent and Hazrati, 1995). DARPP-32 (dopa-
mine and adenosine 3, 5-cAMP-regulated phosphoprotein, 32
kDa), a central mediator of signal transduction pathways in the
dopaminoceptive MSNs, is expressed in90% of striatal MSNs
and is the most commonly used marker of this mature neuronal
subtype (Gustafson et al., 1992; Ouimet et al., 1998; Greengard et
al., 1999; Svenningsson et al., 2004). Identification of the molec-
ularmechanisms that regulate DARPP-32 expression will aid in a
rational design of therapeutic strategies to modulate expression
of DARPP-32 and likely other striatal-enriched genes, either in
neuropathological conditions of the striatumor for the induction
of a striatal phenotype in stem cells.
A number of TFs that regulate neurogenesis, migration, and
differentiation of MSNs have been identified, including Dlx1,
Dlx2, Dlx5, Dlx6, Nolz-1, Isl-1, Mash1, bcl11b/CTIP2, and
Gsh1/2. They are present during embryonic development and are
essentially undetectable after the first postnatal week, with the
exception of CTIP2 (Jain et al., 2001; Chang et al., 2004; Arlotta et
al., 2008). None of these has been demonstrated to bind to
Ppp1r1b sequences or to be sufficient for induction of DARPP-32
during development or in the adult.
We demonstrated that the promoter and intragenic regions of
DARPP-32, collectively termed D9 (genomic elements from
DARPP-32 encompassing 9 kb), selectively direct transgene ex-
pression to MSNs (Bogush et al., 2005; Brown et al., 2008),
whereas the 2.1 kb of 5 UTR sequence alone does not direct
expression to any region of the CNS (Blau et al., 1995). In this
study, we sought to characterize the function of a region in intron
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IV of the Ppp1r1b gene, also known as H10. Our interest in this
particular sequence arose from its high conservation among spe-
cies and its location in a region of the DARPP-32 gene that is
included in D9 (Bogush et al., 2005). After the identification of
multiunit complexes between H10 and striatal nuclear proteins,
theprotein-binding sitewas determined.We found that theTF early
growth response-1 (Egr-1) binds toH10 in vitro and in vivo. Impor-
tantly, we report that Egr-1 is sufficient to induce DARPP-32
expression in vitro and is required for the induction of
DARPP-32 by brain-derived neurotrophic factor (BDNF).
Materials andMethods
Phylogenetic analysis of Ppp1r1b intronic sequences. The mouse and hu-
man genomic sequences of Ppp1r1b were retrieved from the National
Center for Biotechnology Information (NCBI)GenBank database. These
gene sequences were aligned pairwise (mouse vs human) using BLAST
(basic local alignment search tool; bl2seq) at NCBI website with the
following parameters: word size 11; reward for match 1; penalty for
mismatch2; gap open penalty 5; gap extension penalty 2; gap
_dropoff  50; and low-complexity filter checked. Only those align-
ments in the intronic regions (mouse) with 70% sequence homology
were considered for additional analysis. ThemVISTA program (Frazer et
al., 2004)was used for comparative sequence analysis of thePpp1r1b gene
across species (mouse, rat, human, orangutan, dog, and horse). F10A
(75%) and H10 (91%), two of the most highly conserved sequences, were
chosen to conduct this study. “H” is for homology and is the species homol-
ogy; “F” includes the search of other striatal-enriched genes and stands for
“family.” Sequences are as follows: F10A, 5-TTTTATTGCCTGGGTAGC
TTACCCACAGGCAGC-3; and H10, 5-AGCCGCCCACACTGTTCC
TTTCC-3.
Preparations of nuclear and cytoplasmic extracts. For preparation of ex-
tracts from brain tissue, mice of either sex were killed by CO2 asphyxiation,
and brain regions were rapidly dissected. Nuclear and cytoplasmic extracts
were prepared as described previously (Schreiber et al., 1989).
Electrophoretic mobility shift assay and super-shift assays. Double-
stranded oligonucleotides (Integrated DNA Technologies) were pre-
pared in annealing buffer (in mM: 20 Tris, 10 MgCl2, 50 NaCl, and 1
DTT) to a final concentration of 5 M. The double-stranded DNA frag-
ments were labeled with [- 32P]ATP and T4 polynucleotide kinase and
purified with Illustra Microspin G-25 columns
(GE Healthcare). Each electrophoretic mobil-
ity shift assay (EMSA) reaction (25–30l) con-
tained 5–10 g of nuclear proteins, 2 g
poly(dI-dC), and 32P-labeled DNA probe in
1 binding buffer (10 mM HEPES, pH 7.9, 30
mM KCl, 1.2% glycerol, 0.5 mM DTT, 1 mM
MgCl2, 0.2 mM PMSF, and 0.1 mM EDTA, pH
8). For competition experiments, 100 excess
unlabeledoligonucleotideswereaddedbefore the
addition of the labeled probe and incubated for
30 min at 4°C. The protein–DNA complexes
were separated on native 6%polyacrylamide gels
in 0.5 Tris borate/EDTA running buffer at 200
V for 2 h. The gels were dried and exposed on
phosphor-screens (GE Healthcare) using the
Typhoon-Trio (GE Healthcare). For super-shift
assays, 5gof rabbit-Egr-1 antibody, clone588
(sc-110X; Santa Cruz Biotechnology), rabbit
polyclonal -SRF antibody, clone G-20 (sc-335;
Santa Cruz Biotechnology), mouse -Sp1 anti-
body, clone 1C6 (sc-420; Santa Cruz Biotechnol-
ogy), or rabbit polyclonal -Egr-2 antibody
(PRB-236P; Covance) were added to each reac-
tion and incubated for 30 min at 4°C before the
addition of the 32P-labeled H10 probe.
The following sequences were used: putative
Sp1 binding site upstream (in bold) of H10
(Ppp1r1b), 5-GTC CTT GTT CCC TCC CCG
CCTTGCGTCTTTGGGAAGCCGCCCACA
CTG TTC CTT TCC-3 (in which the Sp1 and Egr-1 binding sites are un-
derlined); Drd3, 5-CTGTGTTCGCCCACAGTCATAT-3; Baiap2, 5-CC
CGCACCGCCCACACCCCGCG-3; Ppp1r16b, 5-CCCACTCCGCCCA
CAGCTCTTG-3; Klf16, 5-TGGGGTGTGTGGGCGTGTCGCG-3;
Penk1, 5-GTTGGGTTGTGGGCGGGGCTCA-3; Ppp1r1b (5 UTR), 5-
CGCACCAAGCCCACACATGTGA-3; Cpne2, 5-CGCTTCCCGCCCA
CATCCTCCC-3; and Stra13, 5-CTCACAGACACCCGCTCTGAGG-3
(the putative Egr-1 binding sites are underlined).
Southwestern blot analysis. Nuclear proteins (200 g) from either the
brainstem or striatumwere separated by SDS-PAGE (4–12%Bis Tris) in
MES running buffer (Invitrogen) for 1 h at 200 V and transferred to
nitrocellulose membranes for 3 h at 30 V. Southwestern blot analysis was
performed as per Handen and Rosenberg (1997), with some modifica-
tions. The blots were incubated with 20ml of 1 renaturation buffer (10
mMTris-Cl, pH 7.5, 0.1mM EDTA, pH 7.5, 50mMNaCl, 1mMDTT, and
5% milk) for 2 h at room temperature and then prehybridized with 1
hybridization buffer (10mMHEPES and 5% nonfat dry milk) for 30min
at room temperature. Double-stranded H10 oligonucleotides (20 pmol)
were end labeled with 32P to specific activity of 2  105 cpm/ng. The
membranes were hybridized with 1 binding buffer (10mMHEPES, pH
7.9, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.25% nonfat dry milk)
containing 30g of poly(dI-dC) and 6 ng of radiolabeled probe (2 105
cpm/ng) for 1 h at room temperature. The blot was washed three times
with 1 binding buffer for 20 min each, air dried, and exposed for
autoradiography.
Affinity chromatography. Double-stranded, biotin-tagged (5 end of
forward sequence) DNA oligonucleotides corresponding to the H10 or
F10A sequences were prepared to a final concentration of 20 M (Inte-
grated DNA Technologies). Nuclear extract from rat striatum or brain-
stem was used, and reactions were performed with 5 mg of nuclear
proteins, after the determination that mouse and rat extracts yielded
identical patterns on EMSA. Affinity chromatography was performed as
described previously (Gadgil et al., 2001; Jiang et al., 2009; Minig et al.,
2009) with modifications.
Nuclear extracts were precleared by incubation with 250 l of
streptavidin agarose resin (Pierce) for 1 h at 4°C. To purify the pro-
teins of interest from the precleared extract, we combined it with 1 mg
of poly(dI-dC) (Sigma) as carrier DNA and 10 nmol double-stranded
biotin-tagged H10 or F10A oligonucleotide as a control in 1 binding
Figure 1. H10 and F10A sequences are highly conserved across species (mouse, rat, human, orangutan, dog, and horse).
Nucleotides that are not conserved, compared with mouse, are underlined. The numbers depict the location on mouse chromo-
some 11. TSS, Transcription start site; I–VI, Ppp1r1b introns.
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buffer (10 mM HEPES, pH 7.9, 30 mM KCl, 1.2% glycerol, 0.5 mM
DTT, 5 mM MgCl2, 0.2 mM PMSF, and 0.1 mM EDTA, pH 8) to allow
the formation of the protein–DNA complexes in solution. As con-
trols, we combined biotinylated F10A oligonucleotide with striatal
tissue and H10 oligonucleotide with brainstem tissue. The reactions
were incubated with gentle mixing for 15 min at 4°C, 15 min at room
temperature, and then applied to the capture columns, which con-
tained 250 l of streptavidin agarose resin (capacity of 197 pmol
biotin/1l resin). The columnwas washed five times with 1 binding
buffer to remove unbound DNA and protein and was then eluted with
high-salt buffer at room temperature. The optimal elution condition
for the H10-binding proteins as determined by EMSA was 2 M NaCl
buffer (12% glycerol, 20 mM Tris, pH 6.8, 2 M NaCl, 5 mM MgCl2, 1
mM EDTA, and 1 mM EGTA) at room temperature. Eluted proteins
were analyzed by mass spectrometry.
Mass spectrometry. The pH of all three protein samples was adjusted to
8.5 with 100 mM NH4HCO3. Proteins were reduced with 5 mM [tris(2-
carboxyethyl)phosphine]hydrochloride at 37°C for 20min and alkylated
with 10 mM iodoacetamide for 30 min in the dark at room temperature.
A Lys-C digestion (50 ng/sample) was performed for 4 h, followed by
overnight trypsin digestion at 37°C (1:50 enzyme:substrate ratio). The
digestion was quenched by adding trifluoroacetic acid (5%) to achieve a
pH of 2–4. Samples were desalted with ZipTip C18 (Millipore). The
eluatewas dried down, and peptideswere reconstitutedwith 0.1% formic
acid in 2:98 acetonitrile (ACN) in H2O for liquid chromatography/tan-
dem mass spectrometry (LC-MS/MS) analysis. A Waters NanoAcquity
UPLC systemwas interfaced to a Thermo LTQ-Orbitrapmass spectrom-
eter (Thermo Fisher Scientific). Reversed-phase LC was performed on a
Waters BEH130 C18 column (100 m 100 mm, 1.7 m particle size).
Samples were trapped and washed in a Waters Symmetry C18 trap col-
umn (180 m  100 mm, 5 m particle size) before separation in the
nanocolumn. Gradient elution was performed with 0.1% formic acid in
water as solvent A and in ACN as solvent B, with solvent B raised from 1
to 50% in 90 min, then 50 to 85% in the next 10 min at a flow rate of 0.6
l/min. Themass spectrometerwas operated in positivemodewith spray
voltage at 2.5 kV, ion transfer tube voltage at 45 V, and ion transfer tube
temperature at 170°C. A normalized collision energy of 35% and activa-
tion time of 30 ms were applied in MS/MS acquisitions. The top eight
most intense ions were selected for fragmentation in the LTQ-Orbitrap
mass spectrometer. The following dynamic exclusion settings were ap-
plied to precursor ions chosen for MS/MS analysis: repeat count, 1; re-
peat duration, 60 s; and exclusion duration, 240 s. MS/MS spectra were
searched against the UniProtKB rat database (downloaded February
2011) using Sorcerer-SEQUEST (version 27, revision 11; Sage-N Re-
search), Mascot (version 2.3.02; Matrix Science), X! Tandem (version
2007.01.01.1; The Global Proteome Machine Organization), and Scaf-
fold (version 3.0.8; Proteome Software) algorithms (Perkins et al., 1999;
Searle, 2010). Searches were performed with full tryptic specificity (two
missed cleavages): carbamidomethylated cysteine residues as static mod-
ification, deamidated asparagine and glutamine (0.9840 Da), and oxi-
dized methionine, histidine, and tryptophan (15.9949 Da) as
differential modifications. A precursor mass error tolerance of 10 ppm
and default product ion mass error tolerance of above searching algo-
rithms were used.
Chromatin immunoprecipitation assay. Chromatin immunoprecipita-
tion (ChIP) assays were performed as described previously (Thomas et
al., 2008), with some modifications. Mouse striata equal to 100 mg wet
weight were combined for each ChIP reaction. The tissue was fixed with
1% formaldehyde in PBS for 10 min at room temperature, and 2 M
glycine was added at a final concentration of 0.125 M. After washing with
PBS, the tissue was homogenized with 500 l of cell lysis buffer [10 mM
HEPES, pH 8, 85 mM KCl, 0.5%NP40, and 1 protease inhibitors cock-
tail (Roche)] on ice. Sampleswere centrifuged at 2700 g for 10min, and
the nuclear pellet was resuspended in 300 l of nuclei lysis buffer [1%
SDS, 10 mM EDTA, pH 8, 50 mM Tris-8.0, and 1 protease inhibitors
cocktail (Roche)]. Chromatin was sheared into 200 bp–1 kb DNA frag-
ments with a Branson Sonifier 450 (VWR scientific) 12–15 times at set-
ting 3, duty cycle 50%, for 10 s per pulse, while placing the cells on an ice
for 1min between pulses. The samples were then centrifuged at 20,000
g at 4°C for 10–15 min, and 10% of each sample was saved as input. For
immunoprecipitation (IP) of Egr-1–DNA complexes, each sample was
diluted 10 times with 1 dilution buffer (1% Triton X-100, 150 mM
NaCl, 2 mM EDTA, pH 8, 20 mM Tris-8.0, and 1 protease inhibitors
cocktail), followed by the addition of 6g of rabbit Egr-1 antibody, clone
588 (sc-110X; Santa Cruz Biotechnology) or 6 g of rabbit IgG as a
control and incubated overnight at 4°C. Seventy to 100 l of sheep anti-
rabbit IgG beads (Dyna Beads; Invitrogen) were added, and the reactions
were incubated overnight at 4°C. The beadswerewashed three timeswith
low-salt buffer (1%Triton X-100, 0.1% SDS, 150mMNaCl, 2mMEDTA,
pH 8, and 20 mM Tris-8.0, 1), two times with high-salt buffer (1%
Triton X-100, 0.1% SDS, 500 mM NaCl, 2 mM EDTA, pH 8, and 20 mM
Tris-8.0, 1), and one time with TE buffer (10 mM Tris, pH 8.1, 50 mM
NaCl, and 1mMEDTA) and elutedwith 300l of elution buffer (1%SDS
and 0.1 M NaHCO3) at 65°C for 10 min. To reverse the crosslinks, 5 M
NaCl was added to a final concentration of 0.2 M, and 100 g of protei-
nase K was added to each sample and incubated at 65°C overnight, after
which they were incubated with 1 g of RNase for 30 min at 37°C and
Figure 2. H10 and F10A oligonucleotides interact in vitrowith embryonic and adult striatal
nuclear proteins. A, EMSA shows that 32P-labeled F10A and H10 oligonucleotides bind with
proteins in embryonic (E16–17) and adult striatal nuclear extracts. The specificity of the com-
plexeswas determined by the addition of 100-fold excess of unlabeled F10A or H10 oligonucle-
otide as a competitor. * Refers to nonspecific complexes, i.e., not quenched by competitor. B,
EMSA reveals the formation of complexes between H10 and nuclear extracts from adult stria-
tum, hippocampus, cortex, cerebellum, and brainstem.
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then boiled for 15 min. DNA was purified for quantitative PCR analysis
by QIAquick PCR purification kit (Qiagen).
Quantitative reverse transcription-PCR analysis. Primers were designed
with PrimerExpress software (forward, 5-CCCAGCCTTAACCCAG-
TACTGTTC-3; and reverse,5-TGGGCAAGTGGACTGTTCAGAT-
3) and analyzedwith BLAT (basic local alignment tool) of theUniversity
of California, Santa Cruz genome browser. Quantitative reverse
transcription-PCR was performed by SYBR Green-based real-time PCR
using RT2 SYBRGreen qPCRMasterMixes (catalog #PA-012; SABiosci-
ences) according to the instructions of the manufacturer. PCR products
were detected by ethidium bromide on a Fujifilm LAS-3000 developer
after electrophoresis on 1%Tris borate–EDTA agarose gel for 1 h at 60 V.
For data analysis, the threshold cycles (Ct) of all replicates were averaged
after dropping reactions with PCR inhibitors or a varying slope as deter-
mined from the melt and amplification curves. Each ChIP reaction Ct
value was then normalized to the input DNA Ct value as follows: Ct
(normalized ChIP)  [Ct (ChIP)  Ct (input)  Log2 (input dilution
factor)]. The percentage ofDNA recovered from each IP reaction relative
to the starting DNA was calculated as percentage input as follows: %
input 2 [Ct (normalized ChIP)].
Cell culture and transient transfection. Striatal primary culture cells
were prepared as described previously (Ivkovic and Ehrlich, 1997).
Figure3. Mutation analysis of H10 identifies the sequence 5-CGCCCACA-3, or its complement, as the TF binding site.A, Sequences of 11mutant (Mut) oligonucleotides generated from theH10
oligonucleotide by sequentially mutating 2 nt (underlined). B, EMSA using native H10 and 11mutated H10 oligonucleotides with striatal nuclear proteins shows that mutated nucleotides 2–5 are
required for TF binding. C, Unlabeledmutant oligonucleotides 2–5 are unable to compete for protein bindingwith the native radioactive H10 oligonucleotide. Each “cold”mutant was reactedwith
striatal nuclear proteins before the addition of the 32P-labeled native H10.D, Oligonucleotides containing the sequence 5-CGCCCACA-3with the unique flanking sequences from each gene in the
5UTRofDrd3,Baiap2,Ppp1r16b, and Cpne2genes interact in vitrowith striatal nuclear extract (NE) but notwithbrainstem. Thebandpattern is similar to that seenwithH10except for anadditional,
higher-molecular-weight complex (complex A). Complex B forms between complexes I and II with the Drd3, Baiap2, Ppp1r16b, and Cpne2 sequences and also intermittently with H10. E,
Southwestern blotting (SW) determines that H10 striatal nuclear binding proteins range from 45 to 130 kDa.
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Transfection was performed using electroporation (Amaxa Biosystems).
Neurons were transfected with Egr-1–pIRES2–EGFP vector (Beck et al.,
2008) immediately after dissociation, and electroporationwas conducted
using 4.0 106 cells, 3g of plasmid DNA, and 100l of mouse neuron
nucleofector solution.
Infection assays/viral transduction. Dominant-negative Egr-1 (adnEgr-1)
constructs were in adenovirus (Kundumani-Sridharan et al., 2010). Adeno-
viral infections were performed after cells had attached for 1–2 h. Virus was
added in fresh medium, and cells were harvested after 96 h. BDNF (10 ng/
ml) was added concurrently with virus on the day of plating.Multiplicity of
infection ranged from 100 to 250.
Immunocytochemistry andWestern blot analysis.Both protocols were per-
formed as described previously (Keilani and Sugaya, 2008). Primary and
secondary antibodies included the following: rabbit -DARPP-32, clone
19A3 (2306; Cell SignalingTechnology);mouse-green fluorescent protein
(GFP), clones 7.1 and 13.1 (11814460001; Roche); mouse -WT-1, clone
F-6 (sc-7385; SantaCruz Biotechnology);mouse-GAPDH, clone 6C5 (sc-
32233; Santa Cruz Biotechnology); rabbit -Egr-1, clone 588 (sc-110X;
Santa Cruz Biotechnology); rabbit -histone H3 antibody (09-838; Milli-
pore); horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit
IgG secondary antibodies at concentration of 1:10,000 (Vector Laborato-
ries); and the secondaryantibodiesgreen fluorescentAlexaFluor488andred
fluorescent Alexa Fluor 594 (Invitrogen). Signals were detected by chemilu-
minescenceusing the enhanced chemiluminescenceECL system(Pierce) on
a Fujifilm LAS-3000 developer. The densitometric value of each specific
bandwas obtained usingMultiGauge (Fujifilm) software andnormalized to
GAPDH.
Statistical analysis. Each data point represents triplicate experiments
presented as mean SEM. One-way ANOVAwith Bonferroni’s post hoc
test was performed using GraphPad Prism version 5.00 for Windows
(GraphPad Software). Significance are reported with a p	 0.05.
Results
Intron IV of the Ppp1r1b gene contains seven
conserved sequences
To begin to identify the cis-regulatory elements in the Ppp1r1b
genomic elements (D9) that direct gene expression toMSNs (Bo-
gush et al., 2005), we performed an in silico analysis of D9. We
identified 30 sequences longer than 11 nt that were 70% con-
served across mouse, rat, human, orangutan, dog, and horse
(data not shown). Seven of these non-overlapping conserved re-
gions were located in intron IV. In Figure 1, we show the location
of two of the most highly conserved sequences, also known as
F10A (75%) and H10 (91%).
H10 and F10A form complexes with striatal nuclear proteins
in vitro
To determine whether H10 and F10A participate in the regula-
tion of the Ppp1r1b gene, we searched each sequence for TF bind-
ing sites using MatInspector from Genomatix. Putative sites in
F10A matched those for GCM1 (glial cells missing homolog 1)
and AP2 (activator protein 2), whereas putative sites in H10






Number of unique peptides
Stem–H10 Striatum–F10A Striatum–H10
Uncharacterized protein (Tpr) 267 D3ZNM2 0 0 2
Myosin-9 (Myh9) 226 Q62812 0 0 2
Uncharacterized protein (Rock2) 167 D3ZZU3 (1) 0 0 2
-Actinin-4 (Actn4) 105 Q9QXQ0 0 0 2
Clathrin coat assembly protein AP180 (Snap91) 94 Q05140 (1) 0 0 2
Uncharacterized protein (Ranbp2) 341 D4A054 0 0 1
Filamin (Flna) 280 C0JPT7 (2) 0 0 1
Uncharacterized protein (Map2) 199 D3ZW41 (3) 0 0 1
Uncharacterized protein (Dhx9)* 150 D3Z9Q9 (1) 0 0 1
Cullin-associated NEDD8-dissociated protein 1 (Cand1)* 136 P97536 0 0 1
Uncharacterized protein (Atp1a3) 112 D3ZE88 (3) 0 0 1
Uncharacterized protein (Mcm2) 102 D3ZP96 0 0 1
Sf3b3 protein (Fragment) (Sf3b3) 101 B5DF12 0 0 1
Transcription intermediary factor 1- (Trim28)* 89 O08629 0 0 1
Uncharacterized protein (App) 83 D3ZP79 (3) 0 0 1
Nucleolin (Ncl)* 77 P13383 (1) 0 0 1
ATP-binding cassette, subfamily E (OABP), member 1 (Abce1) 67 D3ZD23 0 0 1
Uncharacterized protein (Ythdf1) 64 D3ZKJ3 (5) 0 0 1
ATP synthase subunit, mitochondrial (Atp5a1) 60 P15999 0 0 1
Acin1 protein (Fragment) (Acin1) 60 Q5BJU9 0 0 1
NADPH:adrenodoxin oxidoreductase, mitochondrial (Fdxr) 54 P56522 0 0 1
Early growth response-1 (Egr-1)* 54 P08154 0 0 1
Uncharacterized protein (Rbm39)* 50 D4A5G0 (1) 0 0 1
Ferrochelatase (Predicted) (Fech) 48 D3ZBM3 0 0 1
Uncharacterized protein (RGD1560464) 45 D4A063 (1) 0 0 1
Uncharacterized protein (Psip1)* 37 D4A7U3 (3) 0 0 1
-Soluble NSF attachment protein (Napb) 33 P85969 0 0 1
Myristoylated alanine-rich C-kinase substrate (Marcks) 30 P30009 0 0 1
14-3-3 protein epsilon (Ywhae) 29 P62260 0 0 1
SAP domain-containing ribonucleoprotein (Sarnp)* 24 Q498U4 0 0 1
Uncharacterized protein (Ppp1r1b) 22 D4A448 (1) 0 0 1
ADP-ribosylation factor 3 (Arf3) 21 P61206 (2) 0 0 1
Calcineurin subunit B type 1 (Ppp3r1) 19 P63100 (1) 0 0 1
Uncharacterized protein 14 D3ZKL0 0 0 1
Uncharacterized protein 12 D4ADA8 0 0 1
RCG37200 (Timm8a2) 11 D3ZV76 (1) 0 0 1
Crosswise comparison of the proteins identified from the Striatum–H10 reaction to the ones identified from the two control columns, Striatum–F10A and Stem–H10, to eliminate the commonproteins. This refinement reduced the number
of the proteins of interest down to 36. * Indicates proteins with a reported function in gene transcription.
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matched those for GREs (glucocorticoid responsive and related
elements) (Fig. 1). On EMSA, the H10 oligonucleotide formed
DNA–protein complexes in equal levels with both embryonic
and adult striatal nuclear extract (Fig. 2A, lanes 11, 13). These
complexes did not form with the embryonic (Fig. 2A, lane 9) or
adult (Fig. 2B, lane 2) cytoplasmic extract and were depleted on
competition with 100-fold molar excess of unlabeled H10 oligo-
nucleotide (Fig. 2A, lanes 10, 12, 14). Conversely, F10A formed
specific, high-intensity protein complexes with embryonic stria-
tal nuclear proteins but at very low intensity with adult striatal
nuclear proteins (Fig. 2A, lanes 4, 6). Because we are interested in
understanding the regulation of DARPP-32 and MSN-specific
expression in both embryonic and adult
striatum, we focused this study on H10,
with F10A as a control in some assays.
To determine whether the H10–pro-
tein complexes are striatal specific, we re-
peated the EMSA with nuclear extracts
from adult striatum, hippocampus, cor-
tex, cerebellum, and brainstem (Fig. 2B).
Complexes I–IV were of markedly greater
intensity with nuclear proteins from fore-
brain regions relative to brainstem. Un-
like in most H10 gel shifts with striatal
extract, complex I was of lower intensity
relative to other forebrain regions. It was
the only complex visible with cerebellar
extract (Fig. 2B, lane 12). We concluded
that the TF(s) complexing with H10 are
widely expressed throughout the fore-
brain. At least one of them is present in
cerebellum, and, if they are expressed in
brainstem, they are undetectable by
EMSA.
H10 contains a novel GC-rich
protein-binding site
To determine the precise protein-binding
nucleotides inH10, we used EMSA to per-
form a mutation analysis. H10 variants
were created by sequentially mutating 2
nt, resulting in a total of 11 novel se-
quences (Fig. 3A).Mutant 2 showed lower
affinity for the H10-binding proteins rel-
ative to the endogenous sequence (Fig. 3B,
lane 6), whereas mutants 3–5 failed to
complex with striatal nuclear extract (Fig.
3B, lanes 7–9). The new complex with
mutant 3 likely resulted from the genera-
tion of a non-physiologic binding site and
was not further investigated (Fig. 3B, lane
7). Conversely, mutant 2 partially com-
peted with 32P-labeled native H10 oligo-
nucleotide (Fig. 3C, lane 5), whereas
mutants 3–5 were totally unable to com-
pete (Fig. 3C, lanes 6–8). We concluded
that the sequence 5-CGCCCACA-3 or
5-TGTGGGCG-3 is the protein-binding
site in H10. The presence of multiple
complexes derived from TF binding to
such a short, single sequence within H10
suggests that multiple TFs likely compete
for this binding site.
Based on the knowledge that each striatal TF participates in
the regulation of multiple genes, we searched for the sequence
5-CGCCCACA-3 in the 1 kb 5 UTR upstream from the tran-
scription start site of 49 striatal-enriched genes and 49 non-
striatal genes (Desplats et al., 2008). We found that this sequence
is found significantly more frequently in the promoters of
striatal-enriched genes (8 of 49) relative to genes not enriched in
the striatum (2 of 49) (Fisher’s test, one-tailed, p  0.045). Al-
though we did not search in the introns, we hypothesize that we
would have found similar results. We generated oligonucleotides
that included 7 nt upstream and 7 nt downstream of the core
sequence (sequences are detailed in Materials and Methods) and
Figure 4. Super-shift assay demonstrates that Egr-1 binds to H10 and to oligonucleotides derived from the 5 UTR of Baiap2,
Ppp1r16b, Klf16, and Cpne2 and containing the H10 binding site 5-CGCCCACA-3. A, The addition of -Egr-1, but not -SRF,
super-shifts H10 complex I. SS, Super-shift, indicated bywhite arrowheads. Complexes II–IV are unaltered after immunodepletion
of Egr-1 from striatal nuclear extracts (NE). B, -Egr-1 super-shifts complex I from oligonucleotide derived from the 5 UTR of
striatal-enriched expressed genes, Baiap2, Ppp1r16b, and Klf16, and of Cpne2, a ubiquitously expressed gene. SS, Super-shift,
indicated by white arrowheads. C, Two Sp1 binding sites were identified by Genomatix, the first of which is 15 nt upstream of the
Egr-1 binding site and the second overlappingwith that for Egr-1. Addition of-Sp1 did not super-shift any of theH10 complexes.
TSS, Transcription start site; I–VI, Ppp1r1b introns.
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again used EMSA to determine whether these sequences from
other genes bind striatal nuclear proteins in vitro. We tested se-
quences from five striatal-enriched genes (Drd3, Baiap2,
Ppp1r16b,Klf16, and Penk1) in addition to Ppp1r1b and two non-
striatal genes (Cpne2 and Stra13). All the sequences tested except
for Stra13 formed complexes similar to those seen with H10
with the nuclear extract from the adult striatum, albeit at
different intensities. Complexes were not formed with brain-
stem extract. Examples with sequences derived from Drd3,
Baiap2, Ppp1r16b, and Cpne2 are pictured in Figure 3D (lanes
5, 7, 9, 11). The sequences derived from genes other than
Ppp1r1b formed an additional complex (complex A) with nu-
clear extracts from both striatum and brainstem. Also, several
of the sequences, including H10 from Ppp1r1b, formed a com-
plex between I and II (complex B).
Egr-1 binds to H10 in vitro and in vivo
We used Southwestern blotting to determine the approximate
molecular weights of the H10-binding proteins. Brainstem nu-
clear extracts were used as a negative control. Relative to brains-
tem, at least four striatal-enriched proteins were found to bind
H10 (Fig. 3E), with estimated molecular weights at 130, 80, 60,
and 45 kDa.
The H10-binding proteins were purified by affinity chroma-
tography. The identities of the purified proteins were determined
by MS (Table 1). The sequences included two TFs (Egr-1 and
Sarnp), four transcription cofactors (Dhx9, Trim28, Nucleolin,
and Rbm39), and two transcriptional activators (Psip1 and
CAND1). Notably, the glucocorticoid receptor was not identi-
fied.We considered Egr-1 to be a strong candidate as a factor that
binds to H10 in vitro based on its consensus binding site (5-
GCGC/GGGGCG-3) and its molecular weight of 82 kDa. We
confirmed binding of Egr-1 to H10 by the super-shift of complex
I with the addition of -Egr-1 to nuclear extracts from both em-
bryonic and adult striata (Fig. 4A, lanes 4, 10). Immunodepletion
of Egr-1 from striatal nuclear extract abolished formation of
complex I but did not disrupt complexes II–IV, indicating that,
although they bind the same site, they form independently of
Egr-1 (Fig. 4A, lane 14). Finally, super-shift assaywith addition of
-Egr-1 to the EMSA striatal mixes with sequences from Baiap2,
Ppp1r16b,Klf16, andCpneII also resulted in a super-shift of com-
plex I (Fig. 4B), indicating that Egr-1 binds to the 5UTRof these
genes in vitro.
To identify potential Egr-1 interacting proteins, we searched
30 nt upstream and downstream of H10. Worth noting, the ad-
dition of only 1 nt upstream of H10 identified an Egr binding site
that falls on the binding site we identified by the mutational
analysis. However, this nucleotide is clearly not required for
binding of Egr-1, at least in vitro. In addition, we located an Sp1
binding site that overlaps with that for Egr, and another that was
15 nt upstream of the Egr binding site (Fig. 4C). Sp1 and Egr-1
can act synergistically when located on neighboring elements
(Lin and Leonard, 1997; Kaiser et al., 2000; Tai andWong, 2003)
or can antagonize each other by competing for the same site
(Huang et al., 1997; Papanikolaou and Sabban, 2000; Davis et al.,
2003; Tan et al., 2003). To test both possibilities, we performed a
super-shift assay on an oligonucleotide that contained both Sp1
elements. Although a complex appeared that migrates slower
than the Egr-1 complex (complex C), the addition of -Sp1,
either alone or together with -Egr-1, did not super-shift any of
the complexes (Fig. 4C). We concluded that Sp1 does not bind
upstream of Egr-1 nor does it compete with Egr-1 at the complex
I site.
To determine whether Egr-1 binds to H10 in vivo, we per-
formed ChIP followed by quantitative real-time PCR analysis
with mouse striatal chromatin. Chromatin from NIH-3T3 cells,
which do not express DARPP-32, was used as a negative control.
The primers were designed to amplify a 252 bp product that
contains the identified Egr-1 binding site (sequences are in Ma-
terials andMethods). The percentage of theDNA recovered from
the Egr-1 IP reaction was higher than with the IgG IP reaction
from striatal chromatin (*p	 0.05) or the Egr-1 IP reaction from
DARPP-32-negative NIH-3T3 cells (Fig. 5).
Egr-1 is sufficient to induce DARPP-32 expression in primary
striatal neurons and is necessary for induction of DARPP-32
by BDNF
We next sought to determine whether Egr-1 is necessary and/or
sufficient for expression of DARPP-32 in embryonic striatal neu-
rons in vitro. Egr-1–IRES–EGFP plasmid (Beck et al., 2008) was
transfected into primary striatal neurons via nucleofection and
increased the percentage of DARPP-32-immunopositive cells
from 6% in neurons transfected with empty vector to 15% in
neurons transfected with the Egr-1–IRES–EGFP plasmid. Al-
though only 8% of the neurons were transfected with Egr-1–
IRES–EGFP, 79% (***p 	 0.001) of the neurons expressing
EGFPwere alsoDARPP-32 immunopositive. Of the neurons that
were GFP negative in the same wells, only 10% were DARPP-32
immunopositive. In comparison, in empty vector GFP-
transfected neurons, only 15% of the EGFP-positive cells ex-
pressed DARPP-32, and 5% of the EGFP-negative neurons were
DARPP-32 immunopositive (Fig. 6).
BDNF induces expression of both DARPP-32 (Ivkovic et al.,
1997, 1999) and Egr-1 (Minichiello et al., 2002; Alder et al., 2003;
Calella et al., 2007), and addition of BDNF to primary striatal
neurons led to an increase in Egr-1 protein after 90 min and an
increase in DARPP-32 protein after 24 h (Fig. 7A). We hypothe-
sized that BDNF induces DARPP-32 expression via inducing
Egr-1 expression, thereby increasing its binding to intron IV of
Ppp1r1b gene, as shown in Figure 7B.
To determine whether Egr-1 is essential for induction of
DARPP-32 by BDNF, we transduced embryonic striatal primary
neuronal cultureswith either an emptyGFP adenovirus (AdGFP)
Figure 5. Egr-1 binds to the H10 sequence in intron IV of the Ppp1r1b gene in vivo. ChIP
assays were performed with adult mouse striatal and NIH-3T3 chromatin. Quantitative PCR
analysis was performed to measure the amount of DNA recovered with each reaction. Egr-1
enrichment is displayed as percentage of the recoveredDNA to the inputDNA (*p	0.05). Error
bars indicate SEM.
6814 • J. Neurosci., May 16, 2012 • 32(20):6808–6818 Keilani et al. • Egr-1 Induces DARPP-32 Expression
or adnEgr-1. The adnEgr-1 construct contained the transcrip-
tional repressor domain of the Wilms tumor protein WT1
(amino acids 1–307) at theN terminus of the Egr-1 DNAbinding
domain (amino acids 327–427) (Kundumani-Sridharan et al.,
2010), andWestern blotting ofWT1 confirmed the expression of
adnEgr-1 (Fig. 7C). Transduction of primary striatal neurons
with adnEgr-1 slightly reduced DARPP-32 protein level relative
to control (AdGFP). However, transduction of neurons with
adnEgr-1 markedly reduced induction of DARPP-32 by BDNF
(*p	 0.05) (Fig. 7C).
To confirm that BDNF increases Egr-1 binding to Ppp1r1b
gene, we tested the formation of the H10 complexes before and
after treating primary striatal cultures with BDNF for 3 h. The
intensity of all H10 complexes, including the Egr-1 complex, in-
creased as early as 3 h after addition of BDNF (Fig. 7D, lanes 5, 6).
In addition, a slowermigrating complex became apparent, which
appeared similar to complex A in Figure 4B. Complex B also
appeared between I and II and became much more prominent
during BDNF treatment. Egr-1 is a member of a family that in-
cludes Egr-2, Egr-3, and Egr-4, all of which are expressed in the
striatum. Of these, Egr-2 is the likely candidate to be redundant
with Egr-1, because it has a similar DNA binding site and is
modulated by BDNF (Calella et al., 2007). As shown in Figure 7D
(lane 12), the addition of -Egr-2 shifted complexes A and B.
These results indicate that exposure to BDNF increases the bind-
ing of Egr-1 and Egr-2 to Ppp1r1b.
Discussion
This report is part of our continued effort to identifymechanisms
ofMSN-specific gene expression.We have previously identified a
combination of Ppp1r1b genomic regulatory regions, including
introns, that directs transgene expression toMSNs (Bogush et al.,
2005) and, conversely, does not permit expression in other re-
gions that express endogenousDARPP-32. The nextmajor goal is
to identify the requiredTFs and the sequences towhich they bind.
In this study, we identified a conserved sequence, also known as
H10, in the Ppp1r1b intron IV and demonstrated that the TF
Egr-1 binds to this region in vitro and in vivo. Functionally, we
showed that Egr-1 is sufficient to induceDARPP-32 expression in
striatal-derived embryonic neurons and is required for induction
of DARPP-32 by BDNF. It is important to note that BDNF in-
duces expression of -galactosidase (-gal) in neurons prepared
frommice transgenic for D9–IRES–-gal, verifying that D9 con-
tains BDNF-responsive sequences. D9–IRES–-gal was derived
by replacing the Cre recombinase cDNAwith the-galactosidase
cDNA (Bogush et al., 2005; A. Bogush, B. Tang, K. Tang, E. A.
Thomas, M. E. Ehrlich, unpublished observations).
We and others have previously reported that BDNF induces
DARPP-32 transcription in MSNs (Ivkovic and Ehrlich, 1999)
via phosphatidylinositol 3-kinase/Akt and Cdk5 pathways and is
independent of ERK (Stroppolo et al., 2001; Bogush et al., 2007).
The Egr-1 promoter contains both an SRE (serum response ele-
ment) and a CRE (cAMP response element) (Knapska and Kac-
zmarek, 2004). In the hippocampus, BDNF induces the
expression of Egr-1 via the activities of TrkB, MEK, CaMK,
PLC, and CREB (Minichiello et al., 2002; Alder et al., 2003). In
the striatum, BDNF induces the phosphorylation of Elk-1, which
targets the SRE site on Egr-1 (Gokce et al., 2009). Of note, how-
ever, the latter pathway is ERK dependent. BDNF also transiently
increases phosphorylation of CREB in MSNs (Stroppolo et al.,
2001), and it is possible that DARPP-32 induction by BDNF is in
part dependent on Egr-1 induction by phosphorylated CREB.
This process, however, must be context specific because other
inducers of CREB phosphorylation, most notably dopamine and
its agonists, do not alter expression of DARPP-32 in MSNs (Eh-
rlich et al., 1990; Grebb et al., 1990).
The striatumdevelops from the lateral ganglionic eminence, and
the firstMSNs tomature are located inpatches and the lateral streak,
whereas later-born neurons populate thematrix (van der Kooy and
Fishell, 1987). Themature, terminal phenotype of theMSN is char-
acterized by DARPP-32 and other markers (Desplats et al., 2006;
Loboet al., 2006).Manyof these, includingDARPP-32, are enriched
in patch neurons during the embryonic period and become more
diffusely expressed as matrix neurons mature. Others, of course,
remain confined to the patch compartment. Relative to other em-
bryonic brain regions, Egr-1 is enriched in the striatum. In the adult,
it is expressed in multiple brainstem nuclei and in the striatum
(Wells et al., 2011), and it is obviously induced in multiple regions
after neuronal activation. Within the embryonic striatum, Egr-1 is
further enriched in patches, perhaps suggesting a developmental,
regulatory role (Snyder-Keller et al., 2002). Beckwith et al. (1966)
Figure 6. Egr-1 is sufficient to induce DARPP-32 expression in striatal primary neurons in vitro. Primary striatal neurons derived from E15–E17 embryos were transfectedwith empty vector (EV)
GFP (a– c) or Egr-1–EGFP plasmid (d, e). After 24 h, cells were fixed with 4% paraformaldehyde and immunostained with-GFP (green) and-DARPP-32 (red). Single- and double-labeled cells
were counted. Numbers were derived from 20 fields from two separate platings and transfections (***p	 0.001). Scale bars: a–f, 2.0 mm; d–f, 1.2 mm. Error bars indicate SEM.
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hypothesizes that a mature neuronal sub-
type is determined by a group of TFs that
induce a specific set of genes,which together
comprise a “regulon,” a term previously re-
stricted to prokaryotes. Furthermore, cis-
motifs may be bound by multiple TFs,
creating a system for coordinated, master,
regulation of phenotype (Flames andHobert,
2011). Thus, we show that the H10 binding
sequence ismore frequently found in striatal-
enriched genes and that Egr-1 binds to these
sequences in vitro in the presence of distinct
flanking sequences. Thus, Egr-1 may induce
additionalmarkers of thematureMSN.
Egr-1 is a ubiquitously expressed im-
mediate early gene, usually associated
with neuronal plasticity after stimuli that
alter intracellular calcium stores (Knap-
ska and Kaczmarek, 2004; Thiel et al.,
2010). Despite its widespread expression,
many examples exist of regulation of cell-
specific markers by Egr-1, both within
and outside the nervous system (Boyle et
al., 2009). Tissue-specific expression of
proteins may be mediated by cell-specific
TFs but also by unique combinations of
ubiquitously expressed TFs (Hobert et al.,
2010). For example, Egr-1 acts synergisti-
callywithNFATc to regulate expression of
the IL-2 gene in T lymphocytes by binding
independently to adjacent sites within the
IL-2 gene promoter (Decker et al., 1998).
Thus, it is unlikely that Egr-1 alone can
induce the DARPP-32 phenotype in pre-
cursors that have not yet committed to the
MSN lineage but may be sufficient once
the neurons are committed. In both cases,
therefore, Egr-1 almost certainly acts in
concert with other TFs, because induction
of Egr-1 in most cell subtypes does not
induce DARPP-32. For example, Egr-1 is
required in part for BDNF induction of
the tyrosine hydroxylase promoter (Fu-
kuchi et al., 2010), but DARPP-32 is not
expressed in aminergic neurons.
Conversely, the adult Egr-1-null mouse
has a normal level of striatal DARPP-32
(Valjent et al., 2006), indicating that Egr-1 is
ultimately not necessary for expression of
DARPP-32 in vivo. Importantly, develop-
ment of the striatum in the absence of Egr-1
has not been examined, and we know that,
in theBDNF-nullmouse,DARPP-32expression is reducedearlybut
normalizes during the second postnatal week (Ivkovic et al., 1997).
Also, becausewe show that Egr-2 binds to the sameH10binding site
as does Egr-1, Egr-2 may substitute for Egr-1. An Egr-2 regulated
transcription network has been suggested to exist in the striatum,
downstream of the adenosine A2A receptor. However, the involve-
mentofEgr-2 in regulatingDARPP-32 transcription in vivo remains
to be determined.
Our data are highly relevant to the pathophysiology of diseases
in which the striatum plays a role and their potential therapies.
Notably, Egr-1 levels are specifically decreased in the dorsal sub-
region of the striatum inR6/2mousemodel ofHD (Spektor et al.,
2002) and are elevated in the striatum after exposure to drugs of
abuse (Valjent et al., 2000, 2006). More important perhaps is the
potential contribution to cell replacement therapy and to the use
of induced pluripotent stem (iPS) cells for the study of disease
mechanisms. At this juncture, these approaches are hampered by
the inability to induce large numbers of striatal subtype-specific
neurons that are physiologically active and able to properly inte-
grate into the CNS. Evidence is accumulating that the forced
expression of neuronal subtype-specific TFs is able to re-program
cells, e.g., fibroblasts, and to convert embryonic stemcells and iPS
Figure 7. BDNF increases binding of Egr-1 to H10 and requires Egr-1 to induce DARPP-32 expression in vitro. A, Egr-1 level
increases 1.5 h after addition of BDNF to primary striatal neurons.Western blotwas performed on total cellular lysates. As reported
previously, DARPP-32 level is increased24hafter treatment.B,The schematic showshowBDNF leads to the inductionofDARPP-32
expression after upregulation and binding of Egr-1 to intron IV of the Ppp1r1b gene. C, Egr-1 function is inhibited in BDNF-treated
primary striatal neurons via transduction with adnEgr-1 adenovirus (Kundumani-Sridharan et al., 2010), leading to a decrease in
induction of DARPP-32 by BDNF. WT1 antibody was used to confirm the transduction of the fusion protein (*p	 0.05, **p	
0.01). Error bars indicate SEM. D, EMSA with equal amounts of nuclear extract from treated and untreated neurons shows that
BDNF enhances Egr-1 and Egr-2 binding to H10 3 h after treatment. * Indicates nonspecific complexes, i.e., not quenched by
competitor. NE, Nuclear extract; SS, super-shift; TSS, transcription start site.
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to a specific phenotype (Caiazzo et al., 2011; Son et al., 2011;
Sa´nchez-Dane´s et al., 2012). Perhaps the most successful MSN
differentiation program to date is that of Aubry et al. (2008) in
which neural precursors are treated with BDNF and then with
BDNF and valproic acid for terminal differentiation into MSN-
like neurons. Multiple markers were assayed, although not their
colocalization, and only extrinsic signals were used to induce
differentiation. In addition to our findings, Egr-1 was recently
identified in a novel SOX2-positive neuronal progenitor cell pop-
ulation in developing NeuN-positive striatal neurons, indicating
a role for Egr-1 in both intermediate and terminal differentiation
of MSNs and perhaps in maintenance of the differentiated phe-
notype (Wells et al., 2011).
In summary, our study is the first to identify a TF, Egr-1, that
directly interacts with and regulates Ppp1r1b gene expression in
MSNs. In addition, we demonstrate that it acts downstream of
BDNF, a major regulator of DARPP-32 and other markers of the
differentiated MSN. As we continue to identify specific TFs that
can directly induce DARPP-32, it will be critical to test them for
their utility in driving an MSN phenotype, the identification of
which should include multiple, colocalized markers and physio-
logical properties.
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